This well-established pathway is a key target for the development of a new generation of weight loss pharmacotherapies, including GLP-1 agonists (discussed in detail below) and the MC4R agonist, setmelanotide [27], which is used to treat monogenic and syndromic forms of obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.